Trial · NCT00947154
Trial of Aripiprazole in Trichotillomania
NCT00947154, Not applicable, Completed, Stanford University; results first posted 2015-06-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial of Aripiprazole in Trichotillomania. Trials, record NCT00947154. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00947154
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial of Aripiprazole in Trichotillomania
- NCT number
- NCT00947154
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 12 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Trichotillomania
- Interventions
- aripiprazole
- First posted
- 2009-07-27
- Last updated
- 2015-06-16
- Results first posted
- 2015-06-16
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mass General Hair Pulling Scale | Change from baseline to week 8 | A brief, self-report instrument for assessing repetitive hairpulling. Seven individual items, rated for severity from 0 to 4, assess frequency and intensity of urges to pull, ability to control the urges, frequency of pulling, attempts to resist pulling, success in resisting, and associated distress. Statistical analyses indicate that the seven items form a homogenous scale for the measurement of severity in trichotillomania. Higher scores indicate greater severity of hair pulling. Total score can range from 0 to 28. |
| Primary | Mass General Hair Pulling Scale, Actual Pulling Subscale | change from baseline to end of week 8 | Sum of scores for items 4, 5 and 6 from the Mass General Hair Pulling Scale (Frequency of Pulling, Attempts to Resist Pulling, Control Over Hair Pulling). Score can range from 0 to 12; higher scores indicate more severe hair pulling. |
| Secondary | CGI-I Score of 1 or 2 (Very Much or Much Improved) | At week 8 | CGI = Clinical Global Improvement 7-item scale, from very much worse to very much better. |
| Secondary | Clinical Global Impressions Improvement (CGI-I) | At week 8 | The CGI-I is a clinician rated scale ranging from 0 (not assessed) to 7 (very much worse), with intermediate scores of 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse). The clinician is rating the overall change in the patient's clinical condition. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mass General Hair Pulling Scale | Change from baseline to week 8 | 11 of the 12 subjects initially enrolled. One was lost to follow-up after baseline visit. | units on a scale | MEAN |
| SECONDARY | CGI-I Score of 1 or 2 (Very Much or Much Improved) | At week 8 | 11 of the 12 subjects initially enrolled. One subject was lost to follow-up after the baseline visit. | participants | NUMBER |
| PRIMARY | Mass General Hair Pulling Scale, Actual Pulling Subscale | change from baseline to end of week 8 | 11 participants. 1 participant was lost to follow-up after week 1. | units on a scale | MEAN |
| SECONDARY | Clinical Global Impressions Improvement (CGI-I) | At week 8 | 11 participants. 1 participant lost to follow up after week 1 | percentage completers with score 1 or 2 | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mass General Hair Pulling Scale | Open-label Aripiprazol | -7.8 | Standard Deviation 7.8 | units on a scale | |
| CGI-I Score of 1 or 2 (Very Much or Much Improved) | Open-label Aripiprazol | 7 | participants | ||
| Mass General Hair Pulling Scale, Actual Pulling Subscale | Open-label Aripiprazol | -3.9 | Standard Deviation 4.1 | units on a scale | |
| Clinical Global Impressions Improvement (CGI-I) | Open-label Aripiprazol | 64 | percentage completers with score 1 or 2 |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Open-label Aripiprazol | 12 | |
| Overall Study | COMPLETED | Open-label Aripiprazol | 11 | |
| Overall Study | NOT COMPLETED | Open-label Aripiprazol | 1 |
Source ClinicalTrials.gov
Adverse events7
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | akathisia | Nervous system disorders | Open-label Aripiprazol | 6 | 11 | |
| other | insomnia | Psychiatric disorders | Open-label Aripiprazol | 4 | 11 | |
| other | anxiety | Psychiatric disorders | Open-label Aripiprazol | 4 | 11 | |
| other | dry mouth | Gastrointestinal disorders | Open-label Aripiprazol | 3 | 11 | |
| other | blurry vision | Eye disorders | Open-label Aripiprazol | 3 | 11 | |
| other | dizziness | Nervous system disorders | Open-label Aripiprazol | 2 | 11 | |
| other | anorgasmia | Reproductive system and breast disorders | Open-label Aripiprazol | 2 | 11 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Open-label Aripiprazol | ||
| Total, other adverse events | Open-label Aripiprazol | 11 | 11 |
| Total, serious adverse events | Open-label Aripiprazol | 0 | 11 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21694623 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00947154
GET https://conductscience.org/api/trials/v1/NCT00947154/registered